In 2023, Rohto Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Rohto Pharmaceutical has also provided a category-level breakdown for 11 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
Metric (tCO2e) | 2023 | 2022 | 2021 | 2020 - 2017 |
---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Create your Tracenable account today and download up to 5 company datasets of your choice for free. No credit card required.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Rohto Pharmaceutical’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.
In 2023, the total operational greenhouse gas (GHG) emissions of Rohto Pharmaceutical amounted to 12,722 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Rohto Pharmaceutical decreased by 4.52%, showing that the company has made progress in taking action to reduce the climate impact of its operations. a
In 2023, the total Scope 1 emissions of Rohto Pharmaceutical were 7,613 metric tons of CO₂ equivalent (tCO₂e). a
Since 2018, Rohto Pharmaceutical's Scope 1 emissions have increased by 58.6%, reflecting a rising long-term trend in Scope 1 emissions over time. a b
Compared to the previous year (2022), Rohto Pharmaceutical's Scope 1 emissions increased by 3.05%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
In 2023, Rohto Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 5,109 tCO₂e using the market-based method. a
Compared to the previous year (2022), Rohto Pharmaceutical's Scope 2 emissions (Market-Based) fell by 13.93% in 2023, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption. a
In 2023, Rohto Pharmaceutical reported its Scope 2 emissions using the market-based method. a
In 2023, Rohto Pharmaceutical reported 227,516 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a
The 2023 disclosure of Rohto Pharmaceutical includes a breakdown across 11 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2022, demonstrating consistent Scope 3 emissions reporting coverage year over year. a
In 2023, Rohto Pharmaceutical reported total Scope 3 emissions of 227,516 metric tons of CO₂ equivalent (tCO₂e). a
Approximately 98.04% of these emissions originated from upstream activities such as purchased goods and capital goods, while 1.96% came from downstream activities like product use, distribution, and end-of-life treatment. a
Compared to the previous year (2022), Rohto Pharmaceutical's Scope 3 emissions increased by 17.51%, suggesting that the company faced challenges in reducing emissions across its value chain. a
In 2023, Rohto Pharmaceutical reported emissions for 11 out of the 15 Scope 3 categories defined by the GHG Protocol. a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2023, the largest contributors to Rohto Pharmaceutical's Scope 3 emissions were: a
In 2023, Rohto Pharmaceutical reported a total carbon footprint of 240,238 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 16.09% increase compared to 2022, suggesting a rise in emissions across its operations or value chain. a
The largest contributor to Rohto Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 94.7% of the company's total carbon footprint, followed by Scope 1 emissions at 3.17%. a